Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,827.98 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98. Following the completion of the transaction, the insider directly owned 1,161,128 shares in the company, valued at $9,323,857.84. The trade was a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.06, for a total transaction of $101,002.02.
• On Friday, May 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.23, for a total transaction of $103,835.41.

Xeris Biopharma Stock Performance

Xeris Biopharma stock traded up $0.28 during trading hours on Thursday, hitting $8.28. The company had a trading volume of 3,703,283 shares, compared to its average volume of 1,901,927. The firm has a market cap of $1.43 billion, a PE ratio of 138.00 and a beta of 0.62. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. Xeris Biopharma Holdings, Inc. has a one year low of $4.62 and a one year high of $10.08. The firm has a 50-day moving average of $6.51 and a 200 day moving average of $6.61.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Divisadero Street Capital Management LP bought a new stake in Xeris Biopharma during the third quarter worth about $3,308,000. Apella Capital LLC grew its stake in Xeris Biopharma by 2,359.0% during the fourth quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock worth $1,930,000 after buying an additional 235,897 shares in the last quarter. Granahan Investment Management LLC bought a new position in Xeris Biopharma in the 3rd quarter valued at about $2,850,000. Vanguard Group Inc. raised its position in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $739,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

XERS has been the subject of a number of recent research reports. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.